Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.55 |
| ▸ | BLM | P54132 | 1/20 | 0.54 |
| ▸ | LTA4H | P09960 | 1/20 | 0.53 |
| ▸ | GABRR1 | P24046 | 2/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | TBXAS1 | P24557 | 2/20 | 0.46 |
| ▸ | GPR84 | Q9NQS5 | 3/20 | 0.45 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.41 |
| ▸ | ACACB | O00763 | 1/20 | 0.41 |
| ▸ | ACACA | Q13085 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1875958 | 1.00 | ACE2 (0.55) | ACE2BLMLTA4HGABRR1CYP1A2 | |
| SCHEMBL13431069 | 0.93 | BLM (0.61) | ACE2BLMLTA4HGABRR1CYP1A2 | |
| SCHEMBL5977939 | 0.90 | ACE2 (0.64) | ACE2BLMLTA4HGABRR1CYP1A2 | |
| SCHEMBL20612872 | 0.90 | ACE2 (0.64) | ACE2BLMLTA4HGABRR1CYP1A2 | |
| SCHEMBL9001608 | 0.90 | ACE2 (0.64) | ACE2BLMLTA4HGABRR1CYP1A2 | |
| SCHEMBL31073666 | 0.90 | ACE2 (0.64) | ACE2BLMLTA4HGABRR1CYP1A2 | |
| Ammonia Solution, Strong SCHEMBL28565415 | 0.87 | ACE2 (0.61) | ACE2BLMLTA4HGABRR1CYP1A2 | |
| Ammonia Solution, Strong SCHEMBL28565414 | 0.87 | ACE2 (0.61) | ACE2BLMLTA4HGABRR1CYP1A2 | |
| SCHEMBL16330413 | 0.87 | BLM (0.65) | ACE2BLMLTA4HGABRR1CYP1A2 | |
| SCHEMBL7179523 | 0.87 | BLM (0.65) | ACE2BLMLTA4HGABRR1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110105417-A1 | Drug Conjugates | THE CURATORS OF THE UNIVERSITY OF MISSOURI | 2011-05-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110105417-A1 | Drug Conjugates | ABCB1, SLCO2B1, ABCG2 | ACE2 3440/4885BLM 3779/4885LTA4H 954/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.